Jefferies Group’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$1.41M Hold
115,500
0.01% 713
2022
Q2
$1.37M Hold
115,500
0.01% 712
2022
Q1
$2.2M Buy
115,500
+40,700
+54% +$757K 0.01% 659
2021
Q4
$1.99M Buy
74,800
+41,900
+127% +$1.44M 0.01% 787
2021
Q3
$1.35M Buy
32,900
+9,200
+39% +$504K 0.01% 887
2021
Q2
$1.34M Sell
23,700
-19,700
-45% -$728K 0.01% 885
2021
Q1
$1.82M Buy
+43,400
New +$2.47M 0.02% 721

Other funds holding EDIT

Jefferies Group's EDIT Position: Q3 2022 in Review

Jefferies Group increased its Editas Medicine (EDIT) stake by 116% in Q3 2022, buying an estimated $1.43M and bringing the position to 170,142 shares worth $2.08M. The position accounts for 0.02% of the portfolio, ranked #592.

Jefferies Group first reported a position in EDIT in Q4 2019 and has held it in 8 quarters since. 264 funds tracked by Wall St. Rank hold EDIT as of Q3 2022.

  • Jefferies Group held 170,142 shares of Editas Medicine worth $2.08M as of Q3 2022.
  • Jefferies Group bought 91,552 Editas Medicine shares in Q3 2022, an estimated $1.43M.
  • Editas Medicine made up 0.02% of Jefferies Group's portfolio in Q3 2022, its #592 holding.
  • Jefferies Group first reported a position in Editas Medicine in Q4 2019 and has held it in 8 quarters since.
  • 264 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.